about
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the NationaA comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort studyPilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerEstrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.Progesterone and levonorgestrel regulate expression of 17βHSD-enzymes in progesterone receptor positive breast cancer cell line T47D.Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer.Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer.Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer.Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer.Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerCombination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerAnastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerQuality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast CancerTestosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor TreatmentDocetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerHigher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by SurgeryStudy of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity?
P921
Q33321322-225F0E67-67FD-4DDC-B7F8-FA518B8B7C5CQ33499591-D5E5F1E0-1625-4EE1-8E18-4B615C50F53BQ34252972-96DC8D39-D98E-4708-93F1-91D811EA6AB9Q35671180-BC1D2B35-F419-4D47-BE14-A3C15138F1EBQ35687851-25DE1A44-A033-4EA4-AAA1-C0E5619DB59BQ36889647-55433FED-E4EE-4F0D-92E1-2BB3A206F837Q37690018-A796A85D-3B12-4233-8F7C-D433B554D309Q38934402-06C9809C-12C3-412C-A8E9-A205DE315750Q39352439-1934C629-603F-4B26-92A5-D7AF425553C1Q41368686-96C055B5-F808-479B-949B-CB548624FA30Q41443052-65F8C22F-5E85-40B8-938B-492CAF0ECDA0Q43287052-AAB99A89-5F73-46D3-9583-98A86602F794Q44199301-00B1FAC3-ECAF-4E16-AAD0-DAD3596AF5DAQ46120245-7B63DD4E-1DF2-48A3-8B81-39B40652EFA2Q46171341-95F9E0B9-FE49-45D4-9FD5-5717619D636FQ46935016-C078F4FA-C7D7-4FA4-963D-9FBBD8A9925AQ50609661-F2478D11-5E16-4CE9-A314-4C78939A3730Q51064161-6A0FDE8D-2580-418C-BF61-B1B25C5C76D6Q57112011-9A527640-7A04-4EF3-88B5-E6DB178C85A6Q61936011-B8EDCC50-7711-42DC-AE06-B975A1374B63Q61936899-3D101D47-2F92-4B32-B524-D71D50508A2AQ61980529-9B67296B-57CF-4FFD-A095-4A0F52D98755Q62104750-9CCAB745-B553-4585-9F48-9C610A345DB2Q63316114-01C74274-A9FE-45E8-A894-ADBA2DC88FFFQ63316568-5FBCCF49-0B09-4392-A0D5-AC1DE51F2AC4Q63335243-76A2B142-D46E-43DF-9AA5-ADDF644D6E55Q63573352-BD602D5A-5E7E-4756-8EE2-278247D4D534Q63573374-0FFCB90B-DCD5-4CBA-B1C3-7CC976BF9A00Q79452035-87B5C0F8-9B6E-4091-930B-C95A762F0386
P921
description
Human disease
@en
Krankheit
@de
مرض يصيب الإنسان
@ar
name
progesterone-receptor positive breast cancer
@en
type
label
progesterone-receptor positive breast cancer
@en
prefLabel
progesterone-receptor positive breast cancer
@en
P31
P5270
MONDO:0000615
P699
DOID:0060077